David A. Leib

This study shows that modifying monoclonal antibodies to interact with complement factor C1q can enhance or reduce their ability to protect against lethal HSV-1 infection in neonatal mice.

The paper identifies prefusion-specific human antibodies against HSV-2 gB that neutralize both HSV-1 and HSV-2 and protect neonatal mice.

This study shows that gB-targeting antibodies protect neonatal mice from HSV infection, requiring both neutralization and Fc effector functions, with transgenerational protection achievable via AAV-mediated delivery.

The study shows engineered antibodies lacking Fc receptor binding improve HSV protection, suggesting vaccine strategies targeting IgG3 could enhance immunity.

This study shows ICP34.5 sustains HSV-1 latency in human neurons by maintaining host translation, with distinct mechanisms in human iPSC-derived neurons versus mouse primary neurons.

This study shows that asymptomatic neonatal HSV infection in mice causes long-term cognitive impairment, highlighting the role of the γ34.5 gene in neurovirulence.